Financial Supervision Authority

Current report No. 15/2019

Date prepared: 27/05/2019

Abbreviated name of the issuer: Mabion S.A.

Subject: The acceptance of the second registration application for MabionCD20 drug for assessment by the European Medicines Agency.

Legal basis: Article 17 paragraph 1 MAR–confidential information.

Content of the report: With reference to the current report no. 13/2019 dated on May 6, 2019 regarding the submission to the European Medicines Agency (EMA) the second registration application ("Duplicate application") for a drug with the working name MabionCD20, the Management Board of Mabion S.A. (“the Company“) informs that on May 27, 2019 it received information about successful completion of validation of above-mentioned application by the European Medicines Agency (EMA) and thereby the acceptance of it into the assessment procedure.

The company informs that the confirmation of acceptance of the application for assessment does not guarantee the product approval by the European Medicines Agency.